On June 23rd, BMI SYSTEM participated as a Gold Sponsor in the PharmaCompliance 2015, which took place in Paris.

The objective of this event was to discuss healthcare ethics and compliance, particularly the transparency of financial relationships between pharmaceutical companies and healthcare professionals and organisations, nationally and globally. It was also a good opportunity, through various presentations, roundtables and workshops, to meet some of the industry’s experts.

Feedback from the US

The PharmaCompliance Paris 2015 was inaugurated by Dr. Shantanu Agrawal, Managing Director and Administrator of the CMS (Center for Medicare & Medicaid Services) and Head of the Sunshine Act in the United States. He presented the feedback from the first publication that took place last September. In the US, the publication of the transfers of values takes place on a dedicated online platform called “Open Payments”, managed by the CMS.

About 25% of US physicians have a financial relationship with healthcare companies through consulting services, speeches at conferences or clinical trials.

The first publication (on data collected in 2013) covered a total of 3.7 billion dollars transfers of values, equivalent to 4.5 million dollars records on the website, from 21 countries and 1,419 companies.

To see beyond transparency

The rest of the morning was organised around presentations and roundtables addressing the following themes:
•    The transposition of the EFPIA Code of Disclosure in France
•    The role and evolution of compliance in the strategy of healthcare companies
•    Data protection

Laurent Clerc, Regulatory Affairs Expert, introduced BMI SYSTEM’s vision on the next challenges, beyond transparency, to be met by healthcare companies.

Indeed, France, like the United States or the Netherlands, has already begun to publish transfers of value to healthcare professionals and organisations.

French pharmaceutical companies are now beginning to question the future challenges arising from this publication: in their relationship with the public and the media, in the way they communicate, but also in the consistency between the budget estimates of the events they organise and the actual expenditures. Finally, companies recognise the need to better manage their financial relationships with healthcare professionals and prevent any risk of conflicts of interest.

Disclosure in France within an international approach

The second part of the PharmaCompliance conference was devoted to practical workshops focused on three main themes: digital projects, transparency and compliance.

Laurent Clerc and Sylvain Hubert, Business Manager of BMI SYSTEM’s British subsidiary, conducted a workshop on the implementation of the “Loi Bertrand” (French law on Transparency) in the context of European self-regulation. The objective of the workshop was to identify the main issues that need to be managed when a pharmaceutical company wants to implement a transparency management tool to cover the EFPIA requirements but also the issues specific to each European country, including France.

With the participants, they followed the whole process of transparency in France, analysed each step (creation of event, registration of participants …) to compare national requirements regarding disclosure with those in the rest of the world: for example, what are the differences and how to integrate them into a more global strategy?